GLP-1 Growth Is Pushing Manufacturing Evidence Earlier
DEICELL SYSTEMS | MARKET PRESSURE BRIEF
July 9, 2026
GLP-1 Growth Is Pushing Manufacturing Evidence Earlier
GLP-1 demand is moving supplier qualification, process-transfer rationale, batch documentation, deviation control, and QMS scope decisions into the foreground earlier for biotech and medtech teams tied to obesity, diabetes, delivery systems, CDMO capacity, and adjacent manufacturing models.
GLP-1 growth is forcing manufacturing evidence into the foreground before many emerging teams are staffed to manage it.
The signal is visible in the data. Deloitte’s 2026 pharmaceutical innovation analysis shows headline late-stage R&D returns improving to 7.0 percent in 2025, but the same analysis shows a much weaker 2.9 percent return when GLP-1/GIP mechanisms are excluded. Average forecast peak sales per asset rose to $598 million in 2025, but the report ties that increase heavily to a small number of high-forecast GLP-1/GIP assets.
That concentration changes the operating question for smaller biotech and medtech teams. The issue is whether manufacturing records, supplier files, transfer assumptions, release evidence, training records, and change decisions can withstand the pressure created when investors, partners, CDMOs, and commercial teams expect GLP-1-related capacity to move faster than the quality system.
KEY SIGNALS
- Value is concentrating around GLP-1/GIP assets: Deloitte reports that GLP-1/GIP assets account for an estimated 38 percent of projected commercial inflows from the 2025 late-stage pipeline. The same analysis reports that excluding GLP-1/GIP mechanisms drops the rate of return to 2.9 percent and average forecast peak sales to $353 million.
- Portfolio risk is becoming more sensitive to fewer programs: In 2025, 54 blockbuster asset-indications, about 9 percent of the late-stage cohort, are projected to generate around 70 percent of total risk-adjusted peak sales. Deloitte also reports that mega-blockbusters increased from six in 2024 to eight in 2025, with average mega-blockbuster value rising 14.7 percent.
- Demand and access pressure are widening: J.P. Morgan Global Research forecasts the global incretin market, including GLP-1s, will reach $200 billion by 2030, and projects U.S. GLP-1 treatment use rising to approximately 25 million people by 2030 from around 10 million in 2025.
- Supply assumptions are changing the manufacturing profile: J.P. Morgan states that oral GLP-1s could reduce cold-chain dependency for some products, while manufacturers are investing in facilities for oral and injectable production. The same source notes that patents are set to expire in major markets, but large capital requirements may limit the supply impact.
Sources: Deloitte pharmaceutical innovation analysis; J.P. Morgan Global Research GLP-1 supply and demand analysis.
THE MARKET SIGNAL
The GLP-1 market is shifting from demand validation to execution exposure.
Deloitte’s analysis shows the pharmaceutical R&D recovery is not evenly distributed. The headline IRR reached 7.0 percent in 2025, but the median stayed close to prior-year levels, moving from 3.8 percent in 2024 to 4.0 percent in 2025. That spread matters because a few GLP-1/GIP programs are carrying a large share of the apparent improvement.
The concentration is also visible at the asset level. Deloitte reports that average forecast peak sales increased from $510 million in 2024 to $598 million in 2025, while GLP-1/GIP assets became a major contributor to projected commercial inflows. The report also states that obesity assets, driven almost exclusively by GLP-1/GIP assets, account for approximately 25 percent of total forecast sales in the late-stage pipeline, up from 1 percent in 2022.
For emerging teams, this is a downstream pressure signal. A platform company, delivery-system developer, medtech supplier, fill-finish partner, analytics provider, device-component supplier, or CDMO-dependent biotech may not own the GLP-1 molecule. It may still be pulled into the manufacturing burden through capacity commitments, component supply, cold-chain decisions, method transfer, packaging controls, labeling changes, clinical supply timelines, or investor diligence.
The pressure is not only volume. It is the evidence trail behind volume.
WHY NOW
The timing matters because demand, access, formulation, and supply assumptions are moving together.
J.P. Morgan’s 2026 analysis links expected GLP-1 market growth to reduced prices, senior access, oral GLP-1 approvals, broader coverage, and global supply expansion. It also reports that GLP-1 agonists were originally approved for type 2 diabetes and have expanded into obesity and weight management, with attention on potential benefits across cardiovascular risk, fatty liver disease, and other conditions.
Access pressure is also becoming more visible. J.P. Morgan notes that most major insurers and Medicare plans cover GLP-1s for type 2 diabetes, while coverage for obesity and weight management has been more limited. The same report describes expanding access discussions through Medicare, Medicaid, employer-sponsored plans, and oral-product pressure.
At the same time, supply remains an operating constraint, not an abstract market variable. J.P. Morgan reports low global penetration, roughly 7 percent of diabetes patients and 2 percent of the obese population using these medications, while also pointing to oral pills and facility investment as potential supply drivers.
That combination creates a specific early-stage risk: teams may receive partner, investor, or customer pressure to scale before their records can explain how scale will be controlled.
THE OPERATING GAP
The operating gap is the distance between projected demand and demonstrable manufacturing control.
A team can have credible science, a strong technical story, and active partner interest while still lacking the evidence package needed to support scale. Under GLP-1-related pressure, informal quality practices become visible quickly. Supplier selection needs a documented rationale. CDMO oversight needs defined ownership. Transfer decisions need acceptance criteria. Deviations need classification, investigation, and closure evidence. Change requests need impact assessment. Training needs role-based records. Batch and lot records need retrieval discipline.
This is where early-stage organizations often expose themselves. Development teams may know why a supplier was chosen, but the supplier file may not show qualification status, approved scope, quality agreement status, audit rationale, material risk, or contingency logic. CMC teams may understand why a process parameter changed, but the change history may not connect the decision to product quality, analytical method impact, stability assumptions, or release criteria. Operations may know that a batch passed, but the batch record may not show a clean path through material receipt, in-process checks, deviations, reconciliation, review, and disposition.
The gap is not solved by building a large QMS too early. Overbuilt systems can create their own failure mode when a small team cannot execute the procedures it has approved. The better control point is phase-appropriate evidence: enough documented structure to show who owns the decision, what record proves execution, which risk justified the control, and what trigger would require the system to expand.
WHAT THIS MEANS FOR BIOTECH TEAMS
For biotech teams tied to GLP-1, obesity, diabetes, metabolic disease, peptide manufacturing, injectable supply, oral formulation, or adjacent therapeutic programs, the pressure will usually appear first in CMC and supplier records.
The highest-risk gap is often transfer logic. A development process, pilot batch, engineering run, clinical batch, or CDMO process may move forward with technical confidence but weak documentation of what changed. If the team cannot show which CPPs, CQAs, analytical methods, material specifications, equipment assumptions, or hold-time constraints were evaluated during transfer, later questions become harder to answer. The problem is not only whether the process worked. The problem is whether the team can defend why the process was considered comparable, controlled, and fit for the next use.
Batch documentation becomes another early pressure point. In a constrained market, batch failures, delayed review, missing attachments, unresolved deviations, and unclear release criteria carry more operational weight. A batch record should not function as a storage location for after-the-fact explanations. It should show that the process was executed under approved instructions, reviewed against defined criteria, and dispositioned by an accountable owner.
WHAT THIS MEANS FOR MEDTECH AND DELIVERY-SYSTEM TEAMS
For medtech, drug-delivery, packaging, device-component, and combination-product-adjacent teams, GLP-1 growth can create pressure even when the company is not developing the drug substance.
Injectable growth can increase scrutiny on device components, packaging systems, labeling, IFU controls, human factors evidence, incoming inspection, supplier quality agreements, and design-transfer records. Oral growth can shift some cold-chain assumptions, but it can also create different control points around packaging, stability, distribution conditions, serialization interfaces, and manufacturing capacity. J.P. Morgan notes that oral pills may remove cold-chain requirements for some use cases, which changes access and distribution assumptions; it does not remove the need for controlled evidence around product configuration, supplier readiness, and change impact.
Medtech teams should be especially careful with inherited assumptions. A component supplier approved for development samples is not automatically qualified for clinical or commercial-facing supply. A design file that supports feasibility does not automatically support design transfer. A packaging change that appears operational may still affect labeling, usability, stability, distribution, complaint handling, or traceability.
STAKEHOLDER LENS
Founders and Executive Leadership
The leadership risk is committing to timelines, partnerships, or capacity assumptions before the evidence system can support them. A founder does not need every mature quality-system element in place before the next milestone. The founder does need a clear view of which records would be requested during diligence, partner review, audit preparation, or CDMO escalation.
Leadership should know which suppliers are approved, which are conditional, which remain technical-only, and which lack a documented qualification path. They should also know whether the QMS can show decision ownership for deviations, changes, supplier additions, transfer acceptance, and batch release.
Quality and Regulatory
The quality and regulatory risk is allowing market urgency to convert informal execution into undocumented precedent. Once a supplier, material, process condition, inspection method, or release practice is used repeatedly, it becomes part of the operating system even if the QMS has not caught up.
Quality should focus on scope control. The current-stage system should define which procedures exist now, which records are required now, which risks justify each control, and which triggers require expansion. That means document control, supplier qualification, training, deviation/nonconformance handling, change control, batch review, and audit readiness should be scaled to the company’s actual exposure, not copied from a commercial-stage template.
Operations, Manufacturing, and CMC
The operations risk is losing the technical rationale behind fast decisions. GLP-1-related work can compress timelines around facility selection, equipment availability, peptide or excipient sourcing, analytical capacity, fill-finish slots, packaging configuration, cold-chain assumptions, and CDMO handoffs.
Operations and CMC should protect the record of why decisions were made. A controlled transfer rationale, supplier decision memo, batch review checklist, method-transfer summary, or change impact assessment can prevent later reconstruction. The goal is not more paperwork. The goal is to avoid relying on memory when a partner, auditor, investor, or regulator asks why the team believed the process was controlled.
READINESS CHECK
A pre-commercial or early-clinical team with GLP-1-related exposure should be able to answer these questions with current records.
- Supplier status: Can the team show which suppliers are approved, conditionally approved, technically evaluated, or not yet qualified?
- Supplier rationale: Does each critical supplier file show scope, material or service risk, qualification basis, quality agreement status, and contingency logic?
- Transfer evidence: Can the team show which process, analytical, equipment, material, packaging, or inspection assumptions changed during transfer?
- Batch control: Do batch records show approved instructions, material traceability, in-process checks, deviations, review, and disposition?
- Deviation closure: Are deviations or nonconformances classified, investigated, assigned to owners, closed with evidence, and trended when recurrence matters?
- Change impact: Do change records assess quality, regulatory, validation, supplier, stability, labeling, packaging, and training impact where applicable?
- Training records: Can the team show that personnel were trained to the procedures they execute, before execution occurred?
- QMS scope: Can leadership explain why the current QMS is sufficient for the company’s stage, manufacturing model, supplier exposure, and regulatory path?
- Deferred controls: Has the team documented what is intentionally deferred and what trigger will require expansion?
- Retrievability: Could the team retrieve supplier, batch, deviation, change, training, and transfer records quickly enough for diligence, audit preparation, or partner review?
If the answer depends on one person’s memory, the control is not yet durable.
DEICELL VIEW
GLP-1 growth is creating an evidence-timing problem for smaller life-science teams.
The market is rewarding speed, capacity, and differentiated access, but quality-system evidence does not appear automatically when demand increases. It has to be designed into supplier selection, transfer decisions, batch execution, deviation handling, change control, training, and record retrieval before the pressure arrives.
The strongest early-stage system is not the largest system. It is the system that can explain its own boundaries. A phase-appropriate QMS should show what exists now, what is deferred, what risk justifies each control, and what evidence will be available when the company faces supplier expansion, CDMO oversight, clinical manufacturing, partner diligence, audit preparation, or regulatory interaction.
For GLP-1-adjacent teams, readiness should be tested at the record level. Can the team show the supplier file, the batch record, the transfer rationale, the deviation closure, the change assessment, and the training record? If those records are incomplete, the next milestone may expose a quality-system gap before it exposes a science gap.
DISCUSS AN OPERATIONAL GAP
DeiCell Systems helps pre-commercial and early-clinical biotech and medtech teams design phase-appropriate GMP and QMS infrastructure before manufacturing pressure exposes undocumented risk.
If your team is preparing for supplier expansion, CDMO oversight, clinical manufacturing, technology transfer, batch-record review, deviation control, change control, or audit readiness, DeiCell can help define the minimum-necessary controls needed for the current stage without overbuilding the system.
AUTHOR / CONTACT
Nathan Jones
Founder & Principal Consultant, DeiCell Systems
For a practical review of this issue, contact DeiCell directly or connect with Nathan Jones on LinkedIn.